HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond

Area of Science:

• Oncology
• Endocrinology
• Genetics

Background:

• Castration-resistant prostate cancer (PCa) often develops due to intra-tumoral androgen synthesis after androgen deprivation therapy.
• The enzyme 3β-hydroxysteroid dehydrogenase isoenzyme-1 plays a crucial role in converting adrenal precursor steroids into potent androgens that fuel PCa progression.

Purpose of the Study:

• To review the mechanisms by which HSD3B1 genotype influences androgen physiology and accelerates castration-resistant PCa.
• To examine the association between HSD3B1 genotype and clinical outcomes in advanced PCa.
• To explore potential links between HSD3B1 genotype and non-PCa phenotypes.

Main Methods:

• Review of current scientific literature on HSD3B1 gene, androgen synthesis, and prostate cancer.
• Analysis of the functional consequences of the HSD3B1 1245 A→C polymorphism (rs1047303).
• Correlation of HSD3B1 genotype with clinical outcomes in patients with advanced prostate cancer.

Main Results:

• A common HSD3B1 single nucleotide polymorphism (1245 A→C) results in a more stable enzyme, leading to increased androgen production from adrenal precursors.
• The adrenal-permissive HSD3B1(1245C) genotype is associated with inferior outcomes in patients with advanced PCa treated with androgen deprivation therapy.
• This genotype correlates with increased sensitivity to pharmacologic blockade of adrenal precursors in metastatic disease.

Conclusions:

• The HSD3B1 genotype significantly impacts androgen metabolism and accelerates the development of castration-resistant prostate cancer.
• HSD3B1 genotype serves as a prognostic biomarker for advanced PCa and may influence treatment strategies.
• Further research into the broader implications of HSD3B1 genotype on steroid physiology and other conditions is warranted.